Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

BACKGROUND: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bersanelli, Melissa, Brunelli, Matteo, Gnetti, Letizia, Maestroni, Umberto, Buti, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278098/
https://www.ncbi.nlm.nih.gov/pubmed/32550862
http://dx.doi.org/10.1177/1758835920915303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278098/
https://www.ncbi.nlm.nih.gov/pubmed/32550862
http://dx.doi.org/10.1177/1758835920915303

Ejemplares similares